Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?
Rossi E, Bersanelli M, Gelibter AJ, Borsellino N, Caserta C, Doni L, Maruzzo M, Mosca A, Pisano C, Verzoni E, Zucali PA. Rossi E, et al. Among authors: bersanelli m. Curr Oncol Rep. 2021 Nov 8;23(12):147. doi: 10.1007/s11912-021-01140-9. Curr Oncol Rep. 2021. PMID: 34748099 Free PMC article. Review.
Chemotherapy in metastatic renal cell carcinoma today? A systematic review.
Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F. Buti S, et al. Among authors: bersanelli m. Anticancer Drugs. 2013 Jul;24(6):535-54. doi: 10.1097/CAD.0b013e3283609ec1. Anticancer Drugs. 2013. PMID: 23552469 Review.
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Santoni M, et al. Among authors: bersanelli m. Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6. Target Oncol. 2015. PMID: 25559290
Combination therapy in kidney cancer: the next revolution?
Buti S, Bersanelli M. Buti S, et al. Among authors: bersanelli m. Lancet Oncol. 2015 Nov;16(15):1441-1442. doi: 10.1016/S1470-2045(15)00325-3. Epub 2015 Oct 22. Lancet Oncol. 2015. PMID: 26482275 No abstract available.
Non-clear-cell renal carcinoma therapy: handle with care.
Buti S, Bersanelli M. Buti S, et al. Among authors: bersanelli m. Lancet Oncol. 2016 Mar;17(3):270-271. doi: 10.1016/S1470-2045(16)00013-9. Epub 2016 Mar 2. Lancet Oncol. 2016. PMID: 26972852 No abstract available.
First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.
Buti S, Bersanelli M, Maines F, Facchini G, Gelsomino F, Zustovich F, Santoni M, Verri E, De Giorgi U, Masini C, Morelli F, Vitale MG, Sava T, Prati G, Librici C, Fraccon AP, Fornarini G, Maruzzo M, Leonardi F, Caffo O. Buti S, et al. Among authors: bersanelli m. Clin Genitourin Cancer. 2017 Aug;15(4):e609-e614. doi: 10.1016/j.clgc.2016.12.024. Epub 2016 Dec 29. Clin Genitourin Cancer. 2017. PMID: 28108284
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G. Iacovelli R, et al. Among authors: bersanelli m. Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29. Urol Oncol. 2017. PMID: 28572027
175 results